Deciphera Pharma Stock Price, News & Analysis

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 4:20 PM ET. The event will be held virtually, and a live webcast can be accessed on the Company’s website under the 'Investors' section. Additionally, the webcast will be available for replay for 90 days post-event. Deciphera focuses on developing innovative cancer treatments, including QINLOCK, its FDA-approved drug for fourth-line gastrointestinal stromal tumor (GIST).

Deciphera Pharmaceuticals (NASDAQ:DCPH) reported fourth quarter 2020 financial results, achieving $19.5 million in net product revenue from QINLOCK, up from $0 in Q4 2019. The company's total revenue for 2020 was $42.1 million, driven by increased sales of QINLOCK. R&D expenses rose to $199 million for the year, while the net loss was $266.5 million, or $4.78 per share. Upcoming milestones include top-line results from the INTRIGUE study and potential EMA approval for QINLOCK. The company has a cash position of $561.3 million to support operations into 2022.

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021, at 11:00 AM ET. This event will take place virtually, and a live webcast will be accessible on the Company’s website under the ‘Events and Presentations’ section. A replay will be available for 90 days post-event. Deciphera focuses on developing innovative cancer treatments, with QINLOCK being its FDA-approved medication for fourth-line gastrointestinal stromal tumors (GIST).

Deciphera Pharmaceuticals (NASDAQ: DCPH) will announce its fourth quarter and full year 2020 financial results on February 9, 2021. The company's management will hold a live conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide updates. Investors can access the call by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) with conference ID 5826559. The webcast will also be available on the company’s website.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has provided a corporate update highlighting key 2021 milestones alongside its participation in the J.P. Morgan Healthcare Conference. The company aims to expand the reach of its FDA-approved drug, QINLOCK, for treating gastrointestinal stromal tumors (GIST). Key objectives include reporting Phase 3 data for QINLOCK, seeking EMA approval, and presenting data for two other drug candidates, vimseltinib and rebastinib. The company aims for significant advancements in its clinical programs throughout 2021.

Deciphera Pharmaceuticals today announced that CEO Steve Hoerter will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 AM ET. A live webcast will be available on the company's website, with a replay archived for 90 days post-event.

Deciphera focuses on developing innovative cancer treatments, leveraging its proprietary switch-control kinase inhibitor platform. Its FDA-approved QINLOCK is specifically for fourth-line gastrointestinal stromal tumor (GIST) treatment, also approved in Canada and Australia.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has completed target enrollment for its Phase 3 INTRIGUE clinical study, testing QINLOCK's efficacy in patients with second-line gastrointestinal stromal tumors (GIST). This randomized, global study involves 426 patients and compares QINLOCK to sunitinib. The primary endpoint is median progression-free survival (mPFS). QINLOCK is already approved for fourth-line GIST in the U.S., Canada, and Australia. Top-line results are expected in the second half of 2021, potentially establishing QINLOCK as a best-in-class treatment.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced that CEO Steve Hoerter participated in a fireside chat ahead of the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place from December 1-3, 2020. The recording of the chat is now accessible on the Company's website under the 'Events and Presentations' section and will be available for 90 days. Deciphera focuses on developing innovative medicines for cancer, with QINLOCK® being its FDA-approved treatment for fourth-line gastrointestinal stromal tumor (GIST).